Results 71 to 80 of about 312,207 (267)
Bulletin de la Dialyse à Domicile, 2019 En France, près de 3 millions de personnes sont touchées par les maladies du rein. L’insuffisance rénale chronique touche environ 80 000 personnes. Sur ces 80 000 per¬sonnes touchées, 44 % d’entre elles bénéficient d’une greffe de rein, et 56 % sont ...
Fabrice Huré
doaj +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Drug Delivery, 2017 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based combination therapy and gene therapy are new strategies to potentially overcome the limitations of TRAIL, however, the lack of efficient and low toxic vectors remains the major ...
Shengpeng Wang +7 more
doaj +1 more source
A DR4, DR5 Targeting Conjugated TRAIL Treatment for Colorectal Carcinogenesis: A Way to Future? [PDF]
Pharmaceutical SciencesTRAIL or tumor necrosis factor-related apoptosis-inducing ligand has been one of the major frontiers for the chemotherapeutic approach to treating carcinogenesis.
Parikshit Roychowdhury +7 more
doaj +1 more source
The NO TRAIL to YES TRAIL in cancer therapy (Review)
International Journal of Oncology, 2007 Treatment of cancer patients with conventional therapies (chemotherapy, hormonal therapy, immunotherapy and radiation) respond initially well and experience prolonged tumor-free survival. However, in many patients tumor recurrences and relapses occur and such tumors exhibit the resistant phenotype i.e.
Ji Yeun, Lee +5 more
openaire +3 more sources
MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology, EarlyView.MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
Combining an improvement to PARMA trailing with trailing analysis
Proceedings of the 4th ACM SIGPLAN international conference on Principles and practice of declarative programming, 2002 Trailing of bindings in the PARMA variable representation is expensive in time and space. Two schemes are presented that lower its cost: the first is a technique that halves the space cost of trailing in PARMA. It can be used with conditional and unconditional trailing.
Schrijvers, Tom, Demoen, Bart
openaire +4 more sources
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
DESIGN OF MOTORCYLE ACTIVE CHASSIS GEOMETRY CHANGE SYSTEM
Perner’s Contacts, 2011 Modern motorcycles have a number of electronic systems supporting their driving stability. These are usually adopted solutions used in automobiles.
Jakub Šmiraus, Michal Richtář
doaj